6533b823fe1ef96bd127f7aa

RESEARCH PRODUCT

Very high specific activity erbium 169Er production for potential receptor-targeted radiotherapy

subject

description

Erbium 169Er is one of the most interesting radiolanthanides for new potential receptor-targeted β− therapy applications due to its low energy β− emissions, very low intensity ɣ rays and the possibility to use 68Ga or 44Sc as companion for diagnostic in a theranostics approach. Currently it can be produced in reactors through the neutron activation of highly enriched 168Er. The low specific activity of the produced carrier-added 169Er is limiting its use for receptor-targeted therapy. Nonetheless it is used for radiosynoviorthesis of small joints. The aim of this work is to develop a new large-scale production method for the supply of very high specific activity 169Er. Highly enriched 168Er target has been irradiated at ILL nuclear reactor and shipped to CERN-MEDICIS. There, the irradiated sample has been mass separated in order to isolate 169Er from the high amount of remaining stable 168Er. The proof of principle for a preclinical dose production has been demonstrated with a collection of ≈17 MBq. The specific activity obtained was ≈240 GBq/mg (≈200 times higher than the product obtained at End of Bombardment – EOB) and the overall separation efficiency was ≈0.2%. Several improvements for the future have been identified and are promising. One of them is the installation of the new laser laboratory at CERN-MEDICIS that will allow to improve the selective ionization of erbium atoms leading to an increase of the efficiency of the method. This method can provide the supply of high specific activity 168Er, first for preclinical studies, and opens also the potential for future large-scale supply. © 2019 This research project has been supported by a Marie Skłodowska-Curie innovative training network fellowship of the European commission’s horizon 2020 program under contract number 642889 MEDICIS-PROMED. This work has been, in part, supported by a grant from the French National Agency for Research called “Investissements d'Avenir”, Equipex Arronax-Plus noANR-11-EQPX-0004 and Labex IRON noANR-11-LABX-18-01.